80 Guest Street
Suite 601
Boston, MA 02135
United States
(617) 500-8099
https://www.compasstherapeutics.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 32
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Vered Bisker-Leib M.D., MBA, Ph.D. | Chief Executive Officer | 806.43k | N/A | 1972 |
Dr. Thomas J. Schuetz M.D., Ph.D. | Co-Founder, President of Research & Development and Vice Chair | 829.56k | N/A | 1961 |
Mr. Neil L. Lerner CPA | Vice President of Finance | N/A | N/A | 1967 |
Mr. Jonathan Anderman J.D. | VP, Head of Legal & Corporate Secretary | N/A | N/A | N/A |
Anna Gifford | Communications Manager | N/A | N/A | N/A |
Dr. Minori Rosales M.D., Ph.D. | Senior VP & Head of Clinical Development | N/A | N/A | 1963 |
Ms. Karin Herrera B.A. | VP & Head of Clinical Operations | N/A | N/A | N/A |
Dr. James Kranz Ph.D. | VP and Head of Chemistry Manufacturing & Controls | N/A | N/A | N/A |
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Compass Therapeutics, Inc.’s ISS governance QualityScore as of 1 April 2024 is 9. The pillar scores are Audit: 9; Board: 8; Shareholder rights: 8; Compensation: 9.